spacejunk: I agree with everything you wrote about the court process and trademark issues.
However;
"I see nothing on the near term horizon in terms of marketed products to give either a negative or positive spin to the companies prospects, and everything else is in Research."
Research pays as well. Biota has obtained 2 deals worth over 100 million each for research milestones for their RSV molecule and their Hep C molecule. They are advancing their cure for the common cold (which is very important in people with pre-existing respiratory disease such as asthma and COAD) and when/if they sign a deal with this one it may be worth much more than 100 million as the molecule will be much more advanced in the trials.
LANI has great potential and IV Relenza is one to watch for.
I respectfully disagree with your statement and think there is always a possibility of a great surprise with this company.
"One last thing, I would be extremely dissapointed if this company ever paid a dividend - so don't hold your breath."
I don't understand why you would be disappointed. They are now making a profit, one of the few Aussie biotechs to do so. If this keeps increasing, as I believe it will, surely they will pay a dividend at some stage?
BTA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
